N/A
Completed N=28
Digital Therapeutic Development of Virtual Cognitive-Affective Training for Opioid Use Disorder
Source: ClinicalTrials.gov NCT05034276 ↗Enrolled (actual)
28
Serious AEs
0.0%
Results posted
Jul 2023
Primary outcomePrimary: Number of Participants With Adverse Events and/or Serious Adverse Events — 2 Participants
Summary
This is a Phase 1 trial that aims to establish the safety of MORE-VR, as well as to collect feasibility, usability, and engagement data, for patients receiving medications for opioid use disorder (mOUD).
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Number of Participants With Adverse Events and/or Serious Adverse Events |
2 | — |
| SECONDARY Engagement |
20 | — |
| SECONDARY Numeric Rating Scale of State Craving |
1.22 | — |
| SECONDARY Numeric Rating Scale of State Positive Affect |
1.23 | — |
Eligibility Criteria
Inclusion Criteria
- Age 18 or older
- DSM-5 opioid use disorder diagnosis
- treated with medications for opioid use disorder (MOUD)
Exclusion Criteria
- Mindfulness intervention experience (MBSR, MBRP)
- Active psychosis or high risk of suicidality
- Cognitive impairment (per self-report or report by clinician)
- Unwilling or unable to remain in MOUD treatment for duration of study
Data sourced from ClinicalTrials.gov (NCT05034276). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.